Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation

Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma

Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform

Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war

J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio